<unk>  (INN) (developmental code name MIM-D3) is a selective, cyclic tripeptide partial agonist of TrkA. (this class of drugs is sometimes referred to as nerve growth factor (NGF) mimetics)<unk>  was first synthesized by Burgess and co-workers at Texas A&M University with the intention of producing TrkA agonists. It is under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and is in phase III clinical trials for this indication.<unk>  is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease.<unk>  is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.
Tavilermide
Mecasermin
Esthiomene
Ecallantide
Palifermin
Eliglustat
Custirsen
Sesquimustard